{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Biotech Intuition","title":"Biotech Daily - Oct 16th, 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/0d66dde4\"></iframe>","width":"100%","height":180,"duration":480,"description":"Daily - Oct 16, 2026 - Show Notes\nGet personalized biotech intelligence and catalyst tracking from SOZO Intuition:\nhttps://sozointuition.com\nCHAPTERS\n00:00 Today's Biotech Brief Lead Stories\n00:42 FDA Approves Roche's Enspryng for Thyroid Eye Disease\n01:17 Enspryng Clinical Profile and SatraGO-2 Efficacy\n02:03 Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data\n02:39 Revita Significantly Reduces Post-GLP-1 Weight Regain\n03:26 Mankind Pharma Acquires Majority in Armed Cell\n03:56 Armed Cell Platform and Strategic Leadership\n04:39 Regulatory Moves: Zilbrysq Autoinjector and Talvey\n05:49 Financings and M&A: City Therapeutics and Samsung\n06:48 Looking ahead\n07:36 SOZO Intuition Platform\nSUMMARY\nCHAPTERS AND SOURCES\n00:00 - Today's Biotech Brief Lead Stories\n00:42 - FDA Approves Roche's Enspryng for Thyroid Eye Disease\nFDA approves Roche's Enspryng satralizumab, a first-in-class IL-6R inhibitor, as the first at-home subcutaneous treatment for thyroid eye disease 2026-10-16:\nhttps://www.roche.com/media/releases/med-cor-2026-10-16\n01:17 - Enspryng Clinical Profile and SatraGO-2 Efficacy\n02:03 - Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data\nFractyl Health reports that Revita met the six-month co-primary endpoint in the pivotal REMAIN-1 study, cutting weight regain after GLP-1 discontinuation…:\nhttps://www.globenewswire.com/news-release/2026/10/16/3382499/0/en/fractyl-health-s-revita-meets-six-month-co-primary-endpoint-in-ongoing-remain-1-pivotal-study-with-highly-statistically-significant-reduction-in-weight-regain-after-glp-1-discontin.html\nOpus Genetics presents positive clinical data from the OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026 2026-10-16:\nhttps://ir.opusgtx.com/press-releases/detail/545/opus-genetics-presents-positive-clinical-data-from-opgx-best1-and-opgx-\n02:39 - Revita Significantly Reduces Post-GLP-1 Weight Regain\n03:26 - Mankind Pharma Acquires Majority in Armed Cell\nMankind Pharma enters CAR-T with a EUR 48 million deal...","thumbnail_url":"https://img.transistorcdn.com/9CRjd85JHtM1TuR9eJILKciqKkE8Zi-g-0T-xOirVCU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZGRl/OGVlNDg2NjQ1MmUx/OTMyMjcxZmY3Zjdk/N2JiYS5qcGVn.webp","thumbnail_width":300,"thumbnail_height":300}